一个月内连抛并购计划 明德生物急什么

Core Viewpoint - Mingde Biological has announced a new acquisition plan to acquire 51% of Hunan Lanyi Medical Equipment Co., Ltd. for a total consideration of 35.71 million yuan, with the potential for full ownership if certain performance conditions are met from 2026 to 2028 [1][2] Group 1: Acquisition Details - The acquisition of Hunan Lanyi will be executed in two phases, with the first phase involving an increase in capital and equity acquisition [1] - Hunan Lanyi is currently focused on the research, production, and service of IVD instruments and reagents, particularly in the area of glycosylated hemoglobin testing [1] - The financial performance of Hunan Lanyi shows losses of approximately 20.68 million yuan and 23.98 million yuan for 2024 and the first three quarters of 2025, respectively [2] Group 2: Strategic Rationale - The acquisition is expected to create a natural complement between the core businesses of Mingde Biological and Hunan Lanyi, enhancing the company's comprehensive service capabilities to medical institutions [2] - Mingde Biological aims to expand its product ecosystem and improve its market position in critical care and chronic disease management through this transaction [2][5] Group 3: Financial Performance and Challenges - Mingde Biological reported revenue of approximately 227 million yuan for the first three quarters of 2025, a year-on-year increase of 0.53%, but its net profit decreased by 83.3% to about 13.52 million yuan [4] - The company faces challenges with slow accounts receivable turnover, with a total of approximately 653 million yuan in accounts receivable and a turnover period of 843.4 days [4] - Hunan Lanyi's net assets were negative, amounting to -38.44 million yuan and -62.42 million yuan at the end of 2024 and the third quarter of 2025, respectively [3]